
News|Articles|June 8, 2026
Master Protocols & IRT: 5 Questions Sponsors Must Ask Before Selecting a Randomisation Partner
Author(s)Jennifer Ross
Master Protocols-including platform, umbrella, and basket trials-offer significant benefits and efficiencies in drug development compared with traditional trial protocols. However, their perpetual nature, adaptive designs, and evolving requirements make randomisation inherently more complex. As a result, implementing and maintaining robust randomisation for Master Protocols can be challenging for sponsors. Selecting the right IRT provider is therefore critical. This paper outlines five essential questions sponsors should ask when evaluating IRT providers for Master Protocols, with a focus on long-term trial success, regulatory readiness, and operational resilience.
Trending on Applied Clinical Trials Online
1
The AI Churn Trap in Life Sciences and How to Break It
2
ACT Brief: Execution Failures and Upstream Origins, European Data Governance Reshaping CROs, and Phase-Dependent Trial Competition
3
Real-World Evidence in Transition: CRO Adaptation to the European Health Data Space Framework
4
ACT Brief: Sponsor Oversight Capability Gaps, Community-Embedded Trial Partnerships, and Trialblazer Timeline Realism
5